Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756019 | 0.86 | GPR119 (0.53) | MAPTLMNAALDH1A1GPR119NAMPT | |
| SCHEMBL16026530 | 0.86 | KMT2A (0.56) | ALDH1A1GPR119SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29199352 | 0.85 | MAPT (0.60) | MAPTLMNAALDH1A1GPR119NAMPT | |
| SCHEMBL426841 | 0.83 | MAPT (0.64) | MAPTLMNAALDH1A1GPR119NAMPT | |
| SCHEMBL16278190 | 0.83 | DDB1 (0.49) | GPR119DDB1CRBNRET | |
| SCHEMBL1128655 | 0.82 | NAMPT (0.52) | MAPTALDH1A1GPR119NAMPTMEN1 | |
| SCHEMBL5573222 | 0.82 | MAPT (0.76) | MAPTLMNAALDH1A1GPR119NAMPT | |
| SCHEMBL531970 | 0.81 | GPR119 (0.51) | MAPTGPR119DDB1CRBN | |
| SCHEMBL17110812 | 0.81 | GPR119 (0.44) | MAPTLMNAALDH1A1GPR119NAMPT | |
| SCHEMBL1428193 | 0.81 | GAA (0.42) | MAPTLMNAALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018129411-A1 | ARYL- AND HETEROARYL-RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS AND LIVER AND KIDNEY DISORDERS | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-07-12 | — | — | WO | disclosed |
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| US-9045484-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2265603-B1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | GEN HOSPITAL CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2014053568-A1 | INDOLYLDIHYDROIMIDAZOPYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2265603-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | The General Hospital Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | MAPT 1350/4885LMNA 3064/4885ALDH1A1 317/4885 |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MAPT 3395/4885LMNA 4025/4885ALDH1A1 354/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MAPT 3395/4885LMNA 4025/4885ALDH1A1 354/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | MAPT 4617/4885LMNA 1922/4885ALDH1A1 4510/4885 |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | MAPT 4617/4885LMNA 1922/4885ALDH1A1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.